Disease or Syndrome – Page 5

Transcarent Appoints Erica Palsis as Chief Legal Officer

2 weeks ago talkbio0Tagged Chief Legal Officer, Erica Palsis, Health care facility, Transcarent

Transcarent; Erica Palsis; Chief Legal Officer; Healthcare; AI

FDA Approves Roche’s Biogen-Partnered Gazyva for Lupus Nephritis

2 weeks ago talkbio0Tagged Biogen, Gazyva, Lupus Nephritis, obinutuzumab, Roche (company), treatment approval, United States Food and Drug Administration

Gazyva; obinutuzumab; Roche; Biogen; FDA; lupus nephritis; treatment approval

Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends

2 weeks ago talkbio0Tagged Astellas, Autoimmune Chronic Hepatitis, Clinical Trials, Kezar Life Sciences, Rett Syndrome, setback, strategic alternatives, Taysha Gene Therapies, TSHA-102, United States Food and Drug Administration, Zetomipzomib

Kezar Life Sciences; FDA setback; strategic alternatives; zetomipzomib; autoimmune hepatitis; Taysha Gene Therapies; Astellas; Rett syndrome; TSHA-102; clinical trials

Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

2 weeks ago talkbio0Tagged Biotechnology, board of directors, Clinical Development, Dimitri Azar, Diorasis, gene therapy, Glaucoma, Ophthalmology specialty, United States Food and Drug Administration

Diorasis Therapeutics; Dimitri Azar; Board of Directors; gene therapy; glaucoma; ophthalmology; biotechnology; FDA; clinical development

CHMP Rejects Sanofi’s Rezurock Over Clinical Data Issues, Recommends Approval of BTK Inhibitor Wayrilz

3 weeks ago talkbio0Tagged Autoimmune thrombocytopenia, belumosudil, cGVHD, CHMP, chronic graft-versus-host disease, Clinical Data, Inosine Triphosphate, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, regulatory approval, Rezurock, Rilzabrutinib, sanofi, Wayrilz

Sanofi; CHMP; EMA; Rezurock; Wayrilz; Belumosudil; Rilzabrutinib; chronic graft-versus-host disease; cGVHD; immune thrombocytopenia; ITP; regulatory approval; clinical data

Recent Advances and News in In Vivo Therapeutic Technologies (2025)

3 weeks ago talkbio0Tagged Acquisitions, Autoimmune Diseases, CAR-T, Cell Therapy, drug delivery innovation, Fast Track, gene therapy, in vivo, nanoparticle delivery, Neoplasms, RNA delivery, United States Food and Drug Administration

in vivo CAR-T; cell therapy; gene therapy; RNA delivery; autoimmune disease; oncology; nanoparticle delivery; drug delivery innovation; FDA fast track; biotech acquisitions

EMD Serono Joins TrumpRx in Affordability Push; Roche Launches DTC Program

3 weeks ago talkbio0Tagged Affordability, CNPV, direct-to-consumer sales, Ditiocarb, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Pergoveris, Programs - Publication Format, Roche (company), serono, tariffs, TrumpRx, White House Executive Order

EMD Serono; TrumpRx; IVF therapies; affordability; fertility drugs; Direct-to-Consumer sales; Roche; DTC program; White House Executive Order; Section 232 tariffs; CNPV program; Pergoveris

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

3 weeks ago talkbio0Tagged AstraZeneca, drug price, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Glucagon-Like Peptide 1, Medicaid, Most-Favored-Nation, Pfizer, Pricing, serono, Trump administration, United States Food and Drug Administration, Voucher

most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

3 weeks ago talkbio0Tagged Biological Factors, CNS disorder, Praxis Precision Medicines, Pricing, public entity

Praxis Precision Medicines; public offering; $525 million; stock offering; share offering; pricing; biopharmaceutical; central nervous system disorders

Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

3 weeks ago talkbio0Tagged Autoimmune Diseases, Celiac Disease, Diabetes Mellitus, Insulin-Dependent, EVOQ, Immune Tolerance, License Agreement, Lupus Vulgaris, MOG antibody disease, NanoDisc, Rheumatoid Arthritis, sanofi

Sanofi; EVOQ Therapeutics; NanoDisc; autoimmune disease; license agreement; immune tolerance; celiac disease; type 1 diabetes; MOG antibody disease; rheumatoid arthritis; lupus